← brief for 2026-08-12 · People & money

FLOW Trial: Are Innovative Treatments Accessible to the Patient Communities in Need?` — NephJC

Page No results yet Not peer reviewed

Key takeaways

A kidney patient advocate shares his view on the FLOW trial. That trial tested the drug semaglutide, a GLP-1 drug, in people with diabetes and kidney disease. His main worry is that helpful new treatments often do not reach lower-income communities who need them most. This is an opinion piece, not a study, so it reports no new results.

Source

Page · Forager · 2026-08-13
https://www.nephjc.com/news/flow-patientvoice